Patents matching “formulation”

US 12343350

Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

Windtree Therapeutics, Inc. · Granted Jul 1, 2025 · Expires Jun 26, 2045

WO 2025137347

FORMULATIONS DE RISANKIZUMAB À HAUTE CONCENTRATION

ABBVIE INC [US] · Granted Jun 26, 2025 · Expires Jun 21, 2045

US 12337199

Stable antibody formulation

REGENERON PHARMACEUTICALS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

US 12329751

Topical roflumilast formulation having antifungal properties

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

US 12331099

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

US 12310956

Topical roflumilast formulation having improved delivery and plasma half-life

ARCUTIS BIOTHERAPEUTICS, INC. · Granted May 27, 2025 · Expires May 22, 2045

US 12312375

Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

Compass Pathfinder Limited · Granted May 27, 2025 · Expires May 22, 2045

US 12311026

Therapeutic uses for sodium thiosulfate formulations

Fennec Pharmaceuticals, Inc. · Granted May 27, 2025 · Expires May 22, 2045

US 12295362

Formulations and processes for CAR T cell drug products

Allogene Therapeutics, Inc. · Granted May 13, 2025 · Expires May 8, 2045

US 12295929

Intravenous baclofen formulations and treatment methods

Regents of the University of Minnesota · Granted May 13, 2025 · Expires May 8, 2045

US 12290520

Methods of use of emulsion formulations of aprepitant

Heron Therapeutics, Inc. · Granted May 6, 2025 · Expires May 1, 2045

US 12285419

Bupivacaine multivesicular liposome formulations and uses thereof

Pacira Pharmaceuticals, Inc. · Granted Apr 29, 2025 · Expires Apr 24, 2045

US 12285435

Multivesicular liposome formulations of dexamethasone

Pacira Pharmaceuticals, Inc. · Granted Apr 29, 2025 · Expires Apr 24, 2045

US 12286400

Isofagomine salts, methods of use and formulations

Takeda Pharmaceutical Company Limited · Granted Apr 29, 2025 · Expires Apr 24, 2045

US 12280089

Dry powder formulation of caveolin-1 peptides and methods of use thereof

The Board of Regents of the University of Texas System · Granted Apr 22, 2025 · Expires Apr 17, 2045

US 12280088

Dry powder formulation of caveolin-1 peptides and methods of use thereof

The Board of Regents of the University of Texas System · Granted Apr 22, 2025 · Expires Apr 17, 2045

US 2025120959

NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE

BIOPROJET PHARMA [FR] · Granted Apr 17, 2025 · Expires Apr 12, 2045

US 12274735

IL-4-fusion formulations for treatment of central nervous system (CNS) tumors

Medicenna Therapeutics Inc. · Granted Apr 15, 2025 · Expires Apr 10, 2045

US 12268678

Formulations of hydroxypyridonate actinide/lanthanide decorporation agents

The Regents of the University of California · Granted Apr 8, 2025 · Expires Apr 3, 2045

US 12268660

Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension

Aardvark Therapeutics, Inc. · Granted Apr 8, 2025 · Expires Apr 3, 2045

US 12268695

Betulin-containing birch bark extracts and their formulation

Amryt Pharmaceuticals Designated Activity Company · Granted Apr 8, 2025 · Expires Apr 3, 2045

US 12264345

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Apr 1, 2025 · Expires Mar 27, 2045

US 12257306

Antiviral prodrugs and nanoformulations thereof

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Mar 25, 2025 · Expires Mar 20, 2045

US 12257277

Adeno-associated virus formulations

Takeda Pharmaceutical Company Limited · Granted Mar 25, 2025 · Expires Mar 20, 2045